Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + Trastuzumab + Capecitabine in HER2+ Breast Cancer
NCT04721977Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tucatinib in breast cancer, sponsored by Pfizer. Started Apr 2021; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04721977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04721977.